S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
NASDAQ:ADAP

Adaptimmune Therapeutics - ADAP Stock Forecast, Price & News

$1.10
+0.01 (+0.92%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.06
$1.12
50-Day Range
$1.09
$1.87
52-Week Range
$1.01
$2.65
Volume
562,736 shs
Average Volume
1.02 million shs
Market Capitalization
$170.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75

Adaptimmune Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
456.4% Upside
$6.12 Price Target
Short Interest
Bearish
1.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of Adaptimmune Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$113,002 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.63) to ($0.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

590th out of 1,005 stocks

Biological Products, Except Diagnostic Industry

104th out of 168 stocks


ADAP stock logo

About Adaptimmune Therapeutics (NASDAQ:ADAP) Stock

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the provision and development of novel cell therapies and novel cancer immunotherapy products to people with cancer. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADAP Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Adaptimmune Announces Changes to Board of Directors
See More Headlines
Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADAP Company Calendar

Last Earnings
11/04/2021
Today
3/25/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADAP
Employees
494
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.12
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+513.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
5 Analysts

Profitability

Net Income
$-165,460,000.00
Net Margins
-609.46%
Pretax Margin
-600.26%

Debt

Sales & Book Value

Annual Sales
$27.15 million
Book Value
$0.50 per share

Miscellaneous

Free Float
127,796,000
Market Cap
$170.13 million
Optionable
Optionable
Beta
2.22

Key Executives

  • Adrian RawcliffeAdrian Rawcliffe
    Chief Executive Officer & Director
  • William C. BertrandWilliam C. Bertrand
    Chief Operating Officer
  • Gavin Wood
    Chief Financial Officer
  • Joanna Brewer
    Chief Scientific Officer
  • Elliot NorryElliot Norry
    Chief Medical Officer













ADAP Stock - Frequently Asked Questions

Should I buy or sell Adaptimmune Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADAP shares.
View ADAP analyst ratings
or view top-rated stocks.

What is Adaptimmune Therapeutics' stock price forecast for 2023?

5 Wall Street analysts have issued twelve-month price targets for Adaptimmune Therapeutics' shares. Their ADAP share price forecasts range from $3.00 to $10.00. On average, they predict the company's share price to reach $6.12 in the next year. This suggests a possible upside of 456.4% from the stock's current price.
View analysts price targets for ADAP
or view top-rated stocks among Wall Street analysts.

How have ADAP shares performed in 2023?

Adaptimmune Therapeutics' stock was trading at $1.46 on January 1st, 2023. Since then, ADAP stock has decreased by 24.7% and is now trading at $1.10.
View the best growth stocks for 2023 here
.

When is Adaptimmune Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our ADAP earnings forecast
.

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) announced its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.04. The biotechnology company earned $1.20 million during the quarter, compared to analyst estimates of $1.20 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 132.29% and a negative net margin of 609.46%. During the same quarter in the prior year, the firm posted ($0.23) EPS.

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG).

When did Adaptimmune Therapeutics IPO?

(ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is Adaptimmune Therapeutics' stock symbol?

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.10%), Bank of America Corp DE (2.89%), Morgan Stanley (1.40%), Endurant Capital Management LP (1.06%), Key Client Fiduciary Advisors LLC (0.18%) and Millennium Management LLC (0.10%). Insiders that own company stock include Adrian Rawcliffe, Cintia Piccina, Elliot Norry, Gavin Wood, James Noble, John Lunger, Lawrence M Alleva, William C Bertrand Jr and William C Bertrand, Jr.
View institutional ownership trends
.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adaptimmune Therapeutics' stock price today?

One share of ADAP stock can currently be purchased for approximately $1.10.

How much money does Adaptimmune Therapeutics make?

Adaptimmune Therapeutics (NASDAQ:ADAP) has a market capitalization of $170.13 million and generates $27.15 million in revenue each year. The biotechnology company earns $-165,460,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

How many employees does Adaptimmune Therapeutics have?

The company employs 494 workers across the globe.

How can I contact Adaptimmune Therapeutics?

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The official website for the company is www.adaptimmune.com. The biotechnology company can be reached via phone at 441235430000, via email at ir@adaptimmune.com, or via fax at 44-12-3543-0001.

This page (NASDAQ:ADAP) was last updated on 3/26/2023 by MarketBeat.com Staff